Anuh Pharma Q3 FY26 PAT up 30% YoY, revenue rises about 24%
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Revenue from operations grew 23.6% YoY to Rs 19,717.81 lakhs in Q3 FY26 versus Rs 15,951.33 lakhs in Q3 FY25. PAT rose 30% YoY to Rs 1,345.10 lakhs. Adjusted EBITDA margin expanded to 12.18% from 10.14% YoY. For 9M FY26, revenue grew 22.9% YoY to Rs 56,954.02 lakhs, though 9M PAT dipped 15.8% to Rs 2,936.47 lakhs. Board also authorized KMPs to determine materiality of events under SEBI LODR.
Strong Q3 with double-digit revenue and profit growth, margin expansion reflects operational strength; full-year picture mixed on 9M numbers.